Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies

Contributing to Advance COVID-19 Therapeutics

IDCRC-VTEU sites supported ACTT 1-4 studies

Results

COVID-19 Vaccine Appears Well-Tolerated and Effective in Developing Antibodies in Small Study of Older Adults

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

IDCRC Sites Across the Nation

View World Map

News from VTEU Trials

Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies

To assess the potential risk of this variant to existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested for neutralizing activity against Omicron and compared to neutralization titers against D614G and Beta in a pseudovirus assay in two different laboratories.

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Letter to the NEJM editor

mRNA-1273 vaccine-induced antibodies maintain Fc-effector functions across SARS-CoV-2 Variants of Concern

Here we profiled the binding and functional capacity of convalescent antibodies and Moderna mRNA-1273 COVID-19 vaccine-induced antibodies across SARS-CoV-2 variants of concern.

Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE Trial

This analysis assessed the impact of mRNA-1273 vaccination on the viral dynamics of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the ongoing Coronavirus Efficacy (COVE) trial.

IDCRC Leadership Group

IDCRC Vaccine & Treatment Evaluation Units (VTEUs)

IDCRC Concept Quick Stats

ICP Status

Approved: 28
Administratively Not Supported: 17
Revise & Resubmit: 6
Withdrawn: 8
Liaisons: 1
EWGs: 2
Not Approved: 29
EMT: 5
Other: 7

EWG Assignment

COVID: 76
Respiratory: 10
STI: 5
Malaria/Topical Diseases: 4
Enteric Infections: 3
Emerging Infections: 5

ECP

Protocol Development: 5
IDCRC Concept Study Underway: 3
Moved forward through other processes: 4
Pending: 5
Not approved: 0
In Process: 6
Hold: 5
Withdrawn: 3
Note: Protocols Transitioned to IDCRC for Protocol Implementation: 5
Other studies in process not from IDCRC concepts: (MOMI-VAX, Moderna Variant, Moderna Boost): 4

IDCRC Citation Statement

Please include the following citation in any publications resulting from direct or indirect IDCRC support:

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

Publications